Although 5-HT2A serotonergic antagonists have been used to treat vascular disease in patients with diabetes mellitus or obesity, their effects on leukocyte-endothelial interactions have not been fully investigated. The gene discussed is HTR2A; the disease is obesity due to melanocortin 4 receptor deficiency.